MarketCapExport financials
Blueprint Medicines Corporation (BPMC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Blueprint Medicines Corporation Financial Ratios 2024-2011 | BPMC
Brief overview of Blueprint Medicines Corporation's market valuation
The review covers five available annual periods spanning 2020 to 2024.
The valuation comparison uses EV/EBITDA 413.6x (median 413.6x), P/S 11.71x (median 13.02x), P/B 19.95x (median 6.46x). Ratios sit near their own comparison base, with an average deviation of 0% from five-year medians.
Capital efficiency is characterized by ROE -22.5%, ROA -5.7%, ROCE -60.1%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
Price, earnings and growth produce a PEG of 5.15x. A high value reduces the cushion if growth slows.
The cash conversion cycle lengthened from -248.1 days to 253.8 days, or 501.9 days. More cash is tied up in operations.
Valuation takeaway
Blueprint Medicines Corporation trades near its familiar ratio range. A new earnings or profitability trend is needed to change the view.
Annual Financial Ratios Blueprint Medicines Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-88.8 | -10.5 | -4.8 | -9.7 | 19.5 | -8.8 | -13.1 | -20.7 | -12.6 | -5.4 | - | - | - | - |
P/S |
11.7 | 21.3 | 13.0 | 34.8 | 7.7 | 46.2 | 69.9 | 142.8 | 32.9 | 25.1 | - | - | - | - |
EPS |
-1.1 | -8.4 | -9.3 | -11.0 | 5.8 | -7.3 | -5.4 | -3.9 | -2.6 | - | - | - | - | - |
EV (Enterprise Value) |
6.74 B | 6.15 B | 3.37 B | 6.34 B | 5.68 B | 3.2 B | 3.16 B | 2.75 B | 931 M | 159 M | -32.7 M | 3.64 M | - | - |
EBITDA per Share |
0.26 | 0.19 | 0.2 | 0.11 | 0.12 | -7.44 | -5.53 | -3.96 | -2.58 | -2.78 | - | - | - | - |
EV/EBITDA |
413.6 | 527.6 | 287.3 | 977.5 | 14.8 | -8.3 | -12.5 | -17.8 | -12.2 | -2.6 | - | - | - | - |
PEG |
-119.54 | -37.78 | -0.52 | -2.75 | 5.15 | 0.25 | 0.35 | 0.43 | -0.9 | 0.28 | - | - | - | - |
P/B |
20.0 | 40.6 | 5.2 | 6.5 | 4.2 | 6.6 | 7.4 | 4.9 | 4.3 | 2.0 | - | - | - | - |
P/CF |
-30.9 | -12.1 | -5.3 | -21.0 | 15.8 | -10.5 | -16.6 | -22.6 | -34.0 | -7.8 | - | - | - | - |
ROE % |
-22.46 | -388.17 | -108.32 | -66.35 | 21.35 | -74.88 | -56.48 | -23.74 | -34.02 | -36.65 | - | - | - | - |
ROA % |
-5.69 | -48.32 | -41.30 | -51.44 | 18.27 | -49.13 | -43.81 | -20.69 | -25.64 | -29.50 | - | - | - | - |
ROCE % |
- | - | - | - | - | -60.10 | -51.49 | -22.48 | -28.54 | -32.23 | - | - | - | - |
Current Ratio |
1.3 | 1.1 | 1.6 | 4.4 | 6.9 | 4.9 | 8.3 | 16.0 | 7.7 | 9.1 | - | - | - | - |
DSO |
42.5 | 48.6 | 43.5 | 32.7 | 1.8 | 128.5 | - | - | 47.0 | 109.3 | - | - | - | - |
DIO |
315.3 | 1088.2 | 527.8 | 309.3 | 3684.8 | - | - | - | - | - | - | - | - | - |
DPO |
104.1 | 159.0 | 113.3 | 129.3 | 3934.7 | - | - | - | - | - | - | - | - | - |
Operating Cycle |
357.8 | 1136.7 | 571.3 | 342.0 | 3686.6 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
253.8 | 977.8 | 458.0 | 212.8 | -248.1 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Blueprint Medicines Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.01 | - | -0.89 | -0.8 | 1.45 | - | -2.2 | -2.19 | -2.15 | - | -2.23 | -2.68 | -1.79 | - | -2 | -1.86 | -1.72 | - | 11.49 | -2.28 | -2.11 | -1.35 | -1.93 | -2.04 | -1.98 | -1.83 | -1.66 | -0.62 | -1.29 | -1.23 | -0.96 | -0.86 | -0.84 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.07 | - | - | - | 0.08 | - | - | - | 0.06 | - | 0.08 | - | 0.03 | - | 0.08 | 0.03 | 0.03 | - | 0.09 | 0.06 | 0.03 | - | 0.08 | 0.05 | 0.03 | - | 0.07 | 0.04 | 0.02 | - | 0.03 | 0.02 | 0.01 | - | 0.04 | 0.03 | 0.01 | - | 0.02 | 0.02 | 0.12 | - | 0.29 | 0.2 | 0.1 | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-4.75 | -4.89 | -70.89 | -95.60 | -111.26 | -139.95 | -160.74 | -116.11 | -85.45 | -54.18 | -63.58 | -50.94 | -36.71 | -24.68 | 18.44 | 19.44 | 20.06 | 27.18 | 12.89 | -50.53 | -63.60 | -74.88 | -79.76 | -76.81 | -61.80 | -56.48 | -45.16 | -33.85 | -32.75 | -23.74 | -25.86 | -27.72 | -31.23 | -34.02 | -34.86 | -35.74 | -35.89 | -36.65 | -7.61 | 14.40 | 33.86 | 50.75 | 13.23 | 10.44 | 8.85 | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-0.22 | -0.26 | -12.36 | -19.67 | -26.13 | -34.72 | -43.85 | -41.02 | -36.95 | -26.34 | -33.25 | -24.12 | -30.25 | -20.98 | 15.91 | 16.66 | 17.12 | 23.25 | 13.88 | -36.34 | -43.24 | -49.13 | -54.63 | -54.77 | -45.69 | -43.81 | -35.79 | -27.59 | -27.26 | -20.69 | -21.36 | -22.05 | -24.06 | -25.64 | -26.82 | -27.94 | -28.51 | -29.50 | -49.77 | -63.74 | -73.08 | -80.69 | -21.04 | -16.60 | -14.08 | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.4 | 1.3 | 1.4 | 1.4 | 1.4 | 1.1 | 1.2 | 1.4 | 1.5 | 1.6 | 1.8 | - | 4.4 | 4.5 | 6.4 | 6.5 | 7.2 | 6.9 | 6.9 | 6.9 | 6.9 | 2.9 | 2.9 | 2.9 | 2.9 | 4.5 | 4.5 | 4.5 | 4.5 | 7.8 | 7.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
47.0 | - | 53.7 | 47.9 | 48.8 | - | 61.3 | 51.6 | 38.6 | - | 13.4 | 35.9 | 39.2 | - | 82.8 | 100.5 | 88.3 | - | 0.9 | 77.6 | 57.4 | 1.2 | 6.6 | 11.8 | 45.4 | 5.7 | 5.3 | 0.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
432.5 | - | 645.1 | 274.8 | 745.8 | - | 549.0 | 678.3 | 678.5 | - | 536.1 | 281.5 | 466.8 | - | 382.6 | 219.5 | 11008.6 | - | 5363.1 | 6165.5 | 16312.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
123.6 | - | 226.1 | 58.8 | 137.8 | - | 228.7 | 344.5 | 191.0 | - | 64.4 | 167.7 | 236.2 | - | 137.2 | 33.3 | 3247.0 | - | 2731.2 | 3139.9 | 17419.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
479.5 | - | 698.8 | 322.7 | 794.7 | - | 610.3 | 730.0 | 717.1 | - | 549.5 | 317.4 | 506.0 | - | 465.4 | 320.0 | 11096.9 | - | 5364.0 | 6243.1 | 16370.2 | 1.2 | 6.6 | 11.8 | 45.4 | 5.7 | 5.3 | 0.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
355.9 | - | 472.7 | 263.9 | 656.9 | - | 381.6 | 385.4 | 526.1 | - | 485.1 | 149.7 | 269.8 | - | 328.2 | 286.8 | 7849.9 | - | 2632.7 | 3103.2 | -1049.0 | 1.2 | 6.6 | 11.8 | 45.4 | 5.7 | 5.3 | 0.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Blueprint Medicines Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 2.2 | 0.92 % | $ 3.62 M |  Israel |
 |
Capricor Therapeutics
CAPR
|
$ 9.47 | 10.5 % | $ 440 M |  USA |
 |
Catalyst Biosciences
CBIO
|
$ 14.59 | 1.58 % | $ 1.3 B | USA |
 |
C4 Therapeutics
CCCC
|
$ 3.33 | 6.39 % | $ 276 M | USA |
 |
Codexis
CDXS
|
$ 1.39 | 2.96 % | $ 121 M | USA |
 |
Cerus Corporation
CERS
|
$ 2.38 | 0.82 % | $ 454 M | USA |
 |
Certara
CERT
|
$ 9.2 | 0.11 % | $ 1.48 B | USA |
 |
Cullinan Management
CGEM
|
$ 15.35 | 0.79 % | $ 925 M | USA |
 |
Compugen Ltd.
CGEN
|
$ 2.38 | 1.28 % | $ 222 M | Israel |
 |
Coherus BioSciences
CHRS
|
$ 1.21 | 2.54 % | $ 142 M | USA |
 |
Celldex Therapeutics
CLDX
|
$ 32.41 | 2.43 % | $ 2.15 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
$ 3.78 | 0.13 % | $ 46.1 M | Israel |
 |
Cellectis S.A.
CLLS
|
$ 1.51 | 2.72 % | $ 151 M |  France |
 |
Cellectar Biosciences
CLRB
|
$ 1.84 | 1.1 % | $ 4.8 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
$ 5.3 | 8.0 % | $ 2.35 M | USA |
 |
Cocrystal Pharma
COCP
|
$ 1.15 | 2.68 % | $ 13 M | USA |
 |
Collegium Pharmaceutical
COLL
|
$ 21.82 | 0.44 % | $ 691 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 115.23 | 0.43 % | $ 12 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 6.82 | 2.87 % | $ 90.8 M | USA |
 |
Cardiff Oncology
CRDF
|
$ 1.21 | 3.42 % | $ 80.9 M | USA |
 |
Curis
CRIS
|
$ 0.84 | 1.21 % | $ 11.1 M | USA |
 |
CorMedix
CRMD
|
$ 7.7 | 0.51 % | $ 555 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 55.32 | 0.02 % | $ 4.97 B |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
$ 11.52 | 0.85 % | $ 910 M | USA |
 |
Champions Oncology
CSBR
|
$ 5.0 | 4.38 % | $ 69.2 M | USA |
 |
CytomX Therapeutics
CTMX
|
$ 2.72 | 2.23 % | $ 375 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.53 | 0.41 % | $ 5.86 M | USA |
 |
Cue Biopharma
CUE
|
$ 25.87 | 1.41 % | $ 2.45 B | USA |
 |
CEL-SCI Corporation
CVM
|
$ 2.06 | 15.73 % | $ 16.5 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 65.91 | 0.41 % | $ 7.92 M | USA |
 |
Daré Bioscience
DARE
|
$ 0.85 | 4.7 % | $ 9.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
$ 11.76 | 1.82 % | $ 1.64 B | France |
 |
DiaMedica Therapeutics
DMAC
|
$ 8.27 | 0.85 % | $ 389 M | USA |
 |
Denali Therapeutics
DNLI
|
$ 20.67 | 0.38 % | $ 3.57 B | USA |
 |
Precision BioSciences
DTIL
|
$ 6.26 | 1.29 % | $ 80.3 M | USA |
 |
Dyadic International
DYAI
|
$ 0.44 | 0.49 % | $ 15.9 M | USA |
 |
Editas Medicine
EDIT
|
$ 2.57 | 0.19 % | $ 228 M | USA |
 |
Edesa Biotech
EDSA
|
$ 4.21 | 18.26 % | $ 23.9 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.5 | 4.73 % | $ 22.8 M | Israel |
 |
Enanta Pharmaceuticals
ENTA
|
$ 13.18 | 4.27 % | $ 281 K | USA |
 |
Entera Bio Ltd.
ENTX
|
$ 2.91 | 8.18 % | $ 134 M | Israel |
 |
Equillium
EQ
|
$ 1.63 | 0.31 % | $ 93.4 M | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 51.49 | 0.02 % | $ 1.39 B | USA |
 |
Evogene Ltd.
EVGN
|
$ 0.4 | 7.89 % | $ 3.15 M | Israel |
 |
Exelixis
EXEL
|
$ 58.41 | 0.91 % | $ 15.9 B | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
$ 3.27 | 3.32 % | $ 240 K | USA |
 |
Fate Therapeutics
FATE
|
$ 2.37 | 0.63 % | $ 282 M | USA |
 |
Fortress Biotech
FBIO
|
$ 2.14 | 1.38 % | $ 59.7 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
$ 10.65 | 0.5 % | $ 304 M | USA |
|
Foghorn Therapeutics
FHTX
|
$ 3.57 | 1.42 % | $ 225 M | USA |